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Abstract
Objectives: The purpose of this study was to assess the safety and performance of Stellarex
Drug-coated balloon (DCB).
Background: DCB coatings differ in excipients, paclitaxel dose, and coating morphologies. Due to
these differences, a class effect with DCBs has not been demonstrated. Consequently, each DCB
needs to be evaluated independently based on its own clinical study results.
Methods: The ILLUMENATE Global Study is a prospective, multicenter, single-arm study. Patients
with intermittent claudication or ischemic rest pain due to superficial femoral artery (SFA) and/or
popliteal peripheral artery disease (PAD) were treated with the Stellarex DCB. The primary efficacy
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endpoint was primary patency, defined as freedom from restenosis with peak systolic velocity
ratio 2.5 or clinically-driven target lesion revascularization (CD-TLR) at 12 months. The primary
safety endpoint was freedom from device and procedure-related death through 30 days postpro-
cedure and freedom from target limb major amputation and CD-TLR through 12 months.
Results: In total, 417 lesions were treated in 371 patients. The mean lesion length was 7.56
5.3 cm, 40.8% of lesions were severely calcified per core laboratory fluoroscopy criteria and
31.3% were total occlusions. Primary patency by independent duplex core lab evaluation was
81.4% and the freedom from CD-TLR was 94.8% day 365 per Kaplan-Meier estimate. The major-
ity of patients experienced improvements in their Rutherford classification (90.3%) and walking
impairment questionnaire score (83.6%) at 12 months compared to baseline.
Conclusions: This study validated previous positive findings and confirms the strong safety profile
and effectiveness outcomes.
K E YWORD S
peripheral arterial disease, drug-coated balloon, superficial femoral artery
1 | INTRODUCTION
Endovascular treatment of symptomatic peripheral atherosclerotic dis-
ease (PAD) of the lower extremities is the preferred and recommended
treatment of choice for many patients today [1,2]. Percutaneous trans-
luminal angioplasty (PTA) is very effective in restoring blood flow but
short-term restenosis rate due to recoil and neointimal hyperplasia is
high and documented to be around 50% at 1 year in recently published
trials [3,4]. The restenosis rate is higher in occlusions and long lesions
as well as in highly calcified lesions [5,6]. Stents have been used to pre-
vent restenosis from elastic recoil, but do not prevent neointimal
hyperplasia due to the mechanical interaction of the stent and the ves-
sel wall [6–8]. Multiple improvements in stent design were imple-
mented to improve primary patency such as improved radial force,
higher flexibility, and more resistance to stent fractures [9]. Results
with paclitaxel-eluting stents in the superficial femoral artery (SFA)
showed a significant improvement of primary patency as compared to
bare metal stents [10,11]. However there is still significant controversy
on their role especially in the popliteal artery [12].
Another approach in treating these lesions is the use of paclitaxel-
coated angioplasty balloons where an active antiproliferative drug is
delivered to the vessel wall while performing the angioplasty [13]. The
absorption of an effective amount of drug into the arterial wall
depends on the drug dose, coating morphology, and the excipient [14].
Differences in drug-coated balloon (DCB) construction can lead to dif-
ferences in efficacy, primary patency rates and clinically driven target
lesion revascularization (CD-TLR) rates [3,4]. Promising patency rates
and target lesion revascularization rates have already been docu-
mented with this technique without the need for a permanent implant
[3,4,15]. A limiting factor in using DCBs has been the amount of cal-
cium in the vessel wall, due to the intrinsic limitations of an angioplasty
balloon in severely calcified vessels and the potential barrier to drug
absorption [16].
The Stellarex DCB (Spectranetics Corp., Colorado Springs, CO) has
a low dose (2 mg/mm2) paclitaxel concentration in a hybrid-crystalline
formulation coupled with the excipient polyethylene glycol (PEG),
designed to limit drug loss and facilitate effective drug tissue transfer.
Initial studies on this DCB have revealed primary patency rates at 12
months of 89.5% in the First-in-Human trial [17], 89.0% in the Euro-
pean Randomized Trial [18], and 82.3% in the ILLUMENATE Pivotal
Trial [19]. The freedom from CD-TLR rate was 90 to 95% in each study
[17–19]. The purpose of the ILLUMENATE Global Study was to
expand on these findings.
2 | METHODS
2.1 | Study Design
The ILLUMENATE Global Study is an international, multicenter, single-
arm study designed to continue to assess the safety and performance
of the StellarexTM in patients with de novo or restenotic lesions in the
SFA and/or popliteal arteries down to the trifurcation. The study
received approval by the independent ethics committees. Patients pro-
vided written informed consent prior to enrollment. Eligible patients
had symptomatic leg ischemia (Rutherford 2–4) with angiographic evi-
dence of stenosis within the superficial femoral artery and/or popliteal
artery down to the trifurcation, total lesion length 200 mm with a
possibility of 1 or 2 target lesions, and reference vessel diameter 4 to
6 mm. Included patients were required to have at least one run-off ves-
sel patent to the foot. Key study inclusion and exclusion criteria are
provided in Table 1. The trial was prospectively registered at Clinical-
Trials.gov (NCT01927068).
2.2 | Procedures
Pretreatment evaluations included a clinical assessment, medical his-
tory, medication history, and assessment for study eligibility. Patients
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who met eligibility criteria were scheduled to undergo treatment with
the DCB. Prior to the study procedure and for the duration of the
study, subjects were required to receive acetylsalicylic acid (ASA) of at
least 81 mg daily. According to the study protocol, patients were rec-
ommended to receive either clopidogrel (preferred medication), prasu-
grel, or ticlopidine per hospital standard of care preoperatively or
should have received a loading dose of this product immediately post-
procedure. It was recommended to continue dual antiplatelet therapy
for a minimum of 4 weeks; however, the optimal duration for each sub-
ject was to be determined by the investigator. Following successful
lesion crossing and predilatation with an uncoated balloon (with a
diameter 1 mm less than vessel diameter), angiographic inclusion and
exclusion criteria were evaluated (Table 1). If these criteria were met,
patients were treated with the Stellarex DCB. No more than two DCBs
were allowed to treat each lesion. In cases of residual stenosis >50%
or flow-limiting dissection (grade D or greater), postdilatation for at
least 2 min using a commercially available uncoated balloon was
required. Provisional stent implantation with a bare metal stent was
allowed if postdilatation failed to resolve the residual stenosis or dis-
section. Patients returned for clinical visits at 1, 6, and 12 months and
are scheduled to continue returning at 24 and 36 months. Each visit
included clinical assessment, functional status, adverse event reporting
WIQ score, EQ-5D, and duplex ultrasound. Patients’ adverse events
will be collected through 5 years.
2.3 | Outcomes
The primary safety endpoints were freedom from device and
procedure-related death through 30 days and freedom from target
limb major amputation and CD-TLR through 12 months. The primary
efficacy endpoint was primary patency through 12 months, defined as
absence of target lesion restenosis (peak systolic velocity ratio 2.5)
and freedom from CD-TLR. Primary patency was evaluated on a per
lesion basis. Technical success was defined as final in-lesion residual
diameter stenosis 50% (as determined by the angiographic core labo-
ratory) without a device malfunction of the study device. Procedural
success (per patient) was defined as lesion success without the occur-
rence of major adverse events during the procedure. Lesion success
required final in-lesion residual diameter stenosis 50% determined by
the angiographic core laboratory. CD-TLR was defined as any revascu-
larization of a restenotic target lesion (peak systolic velocity ratio 2.5
by duplex ultrasound or percent diameter stenosis >50% by angiogra-
phy) associated with a worsening in Rutherford class (increase 1 class)
or ankle-brachial index (ABI) (decrease greater than 0.15 units) that
was referable to the target lesion. Additional outcomes included target
limb major amputation, cardiovascular death, walking capacity using
the Walking Impairment Questionnaire, and quality of life evaluated by
the EQ-5D. Data were regularly monitored and 100% source verified.
Independent core laboratories analyzed all images including duplex
ultrasonography (VasCore, Massachusetts General Hospital, Boston,
MA) and angiography (BIDMC, Angiographic Core Laboratory, Boston,
MA). An independent Clinical Events Committee adjudicated adverse
events and an independent Data Safety and Monitoring Board moni-
tored the study for safety.
2.4 | Data Analysis
Outcomes are reported using the intent-to-treat population, which
includes all patients who were enrolled, as opposed to the per protocol
analysis which excluded patients where treatment deviated from the
protocol, such as stented patients or those who were not predilated.
Continuous data were reported as mean and standard deviation; cate-
gorical data were reported as frequencies and percentages. Longitudi-
nal changes in clinical outcomes were assessed with paired t-test. The
TABLE 1 Key inclusion and exclusion criteria
Key inclusion criteria
Symptomatic leg ischemia requiring treatment of superficial femoral artery and/or popliteal artery up to the trifurcation
Age 18 yr
Life expectancy >1 yr
Rutherford-Becker classification 2–4
De novo or restenotic lesion stenosis within superficial femoral artery and/or popliteal artery
Lesion length 20 cm
Lesion treatable by no more than two devices
Successful wire crossing of lesion
Target reference vessel diameter 4–6 mm
Patent (<50% stenosis) inflow artery
At least one patent (<50% stenosis) tibio-peroneal run-off vessel to the foot
Key exclusion criteria
Female who is pregnant, lactating, or intends to become pregnant; male intending to father children during study
Contraindication to dual antiplatelet therapy
Hemorrhagic stroke within 3 mo
Planned vascular interventions within 14 days before or 30 days after the index procedure
Previous bypass graft to target limb
Chronic renal insufficiency (dialysis dependent, or serum creatinine >2.5 mg/dl)
Acute or subacute intraluminal thrombus in target vessel
Severe calcification that precludes adequate PTA treatment
In-stent restenosis or restenosis of the target lesion following previous treatment with drug-coated balloon
Use of adjunctive therapies (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloon, brachytherapy)
Aneurysm in aorta, target vessel, iliac artery, or popliteal artery
SCHRO€E ET AL. | 499
Kaplan-Meier method was used to evaluate time-to-event data
through 12 months. Data were analyzed with SAS version 9.4. Statisti-
cal significance was set at P < 0.05 for all comparisons unless other-
wise stated.
3 | RESULTS
Between July 2013 and June 2015, 371 patients (417 lesions) were
enrolled at 37 sites in Europe, Australia, and New Zealand (listed in the
appendix). Patients were predominantly male (73.0%) with mean age
68 years. Most patients presented as Rutherford class 2 (33.4%) or 3
(57.7%) and 33.7% of patients had diabetes (Table 2). Lesion character-
istics as assessed by the angiographic core laboratory, are presented in
Table 3. The mean lesion length was 7.565.3 cm, reference vessel
diameter was 4.960.8 mm, and 31% had total occlusions. Severe cal-
cification (assessed and defined by the core lab as calcific radiopacities
noted on both sides of the arterial wall and extending more than 1 cm
of length prior to contrast injection or digital subtraction) was present
in 40.8% of patients. A total of 341 patients (384 lesions) completed
the 12-month follow-up visit. A patient accountability flowchart is pro-
vided in Figure 1.
TABLE 2 Baseline patient characteristics.
Variable Value
Demographics
Age (yr) 68.269.3
Male 73.0% (271/371)
Body mass index (kg/m2) 27.064.2
Clinical presentation
Rutherford Class
1 0.3% (1/371)
2 33.4% (124/371)
3 57.7% (214/371)
4 6.2% (23/371)
5 2.4% (9/371)
Ankle-brachial index 0.7060.20
Medical historya
Smoking history 81.9% (304/371)
Hypertension 79.5% (295/371)
Hyperlipidemia 74.7% (277/371)
Diabetes mellitus 33.7% (125/371)
Cerebrovascular disease 17.3% (64/371)
Myocardial infarction 17.3% (64/371)
Angina 13.2% (49/371)
Chronic obstructive pulmonary disease 13.2% (49/371)
Previous revascularization
Lower limb 42.3% (157/371)
Ipsilateral Limb 26.4% (98/371)
Coronary 33.4% (124/371)
Data reported as mean6 standard deviation (n) or % (n/N).
aVariables with frequency >10% reported.
TABLE 3 Baseline lesion characteristics
Variable Value
No. treated lesions
One 87.6%
Two 12.4%
Lesion typea
De novo 94.0%
Restenotic 6.0%
Lesion location
Proximal SFA 11.1%
Mid SFA 41.8%
Distal SFA 33.2%
Proximal popliteal 9.1%
Mid popliteal 3.8%
Distal popliteal 1.0%
Lesion length (mm) 75.0652.7
Reference vessel diameter (mm) 4.960.8
Diameter stenosis (%) 80.3617.4
Total occlusion 31.3%
Severe calcification 40.8%
0–1 Patent run-off vessel 31.1%
Data reported as mean6 standard deviation (n) or % (n/N).
aPer investigator assessment.
Abbreviations: SFA, superficial femoral artery. FIGURE 1 Patient flow diagram
500 | SCHRO€E ET AL.
Most (98%) patients underwent predilatation with an uncoated bal-
loon before treatment with DCB. Three patients were screen failures
due to the need for adjunctive therapies and 12 were excluded because
of severe calcification that precluded adequate PTA treatment. Mean
DCB inflation time was 3.4 min per lesion. Final in-lesion residual
diameter stenosis was 25612%. Acute success rates were 98% for
lesion success, 96% for technical success, and 97% for procedural suc-
cess (Table 4). A bail-out stent was placed in 17% (72/417) of lesions. Of
the stented lesions, 59.2% (42/71; one lesion unknown) were total
occlusions and 40.3% (27/67; five lesions unknown) were severely calci-
fied at baseline. A total of 81.9% of subjects were on aspirin every day
through the 12-month follow-up visit and 76.5% of subjects received
clopidogrel (or equivalent) for 28 days after treatment. In total, 65.8% of
subjects were on the recommended dual antiplatelet therapy regimen.
3.1 | Follow-Up Data
The freedom from a primary safety endpoint event was 94.8% through
365 days (Figure 2A). There were 20 primary safety events in 19
patients including 19 CD-TLRs, 1 major amputation, and no 30-day
device- or procedure-related death. The major amputation occurred in
a patient who was classified with Rutherford class 5 at baseline (a pro-
tocol deviation) and underwent multiple interventions of the popliteal
target lesion before amputation. The primary effectiveness endpoint,
primary patency, was met in 77.2% (285 of 369) of lesions through the
12-month follow-up interval (day 395). Patency failures included
22 CD-TLRs, 55 lesions that were restenosed per Duplex ultrasound
assessment but did not result in a CD-TLR), and 7 missing 12-month
data where restenosis was identified at an earlier follow-up interval.
TABLE 4 Procedural data
Variable Value
Procedure time (min) 61.0628.5
Fluoroscopy time (min) 10.468.3
Predilatation performed 98.1%
Total inflation time (min) 3.461.8
Flow-limiting dissection 0.3%
Postdilatation 28.3%
Bail-out stent placement 17.3%
Diameter stenosis postprocedure 24.7611.8
Lesion success 97.6%
Technical success 95.8%
Procedural success 97.3%
Data reported as mean6 standard deviation or %.
FIGURE 2 (A) Freedom from a primary safety event through 1 year: the freedom from a primary safety event at day 365 was 94.8% and
92.1% at the end of the follow-up window (day 395). (B) Freedom from loss of primary patency through 1 year: the primary patency rate at
day 365 was 81.4% and 69.1% at the end of the follow-up window (day 395). (C) Freedom from CD-TLR through 1 year: freedom from
CD-TLR at day 365 was 94.8% and 92.1% the end of the follow-up window (day 395). (D) Freedom from loss of primary patency rates of
patients with diabetes and patients without diabetes: primary patency rates of patients with diabetes (blue line) was not different than
patients without diabetes (red line) (day 365 estimates: 81.0% vs. 81.5%, P 5 0.9717 by log rank). Rates at the end of the follow-up win-
dow should be interpreted with caution as the number of patients at risk is low due to subjects being censored prior to day 395, at the
time of the 12-month visit [Color figure can be viewed at wileyonlinelibrary.com]
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The Kaplan-Meier estimate of primary patency was 81.4% at 365 days
(Figure 2B). The Kaplan-Meier estimate for freedom from CD-TLR
through day 365 is 94.8% as shown in Figure 2C. In patients with an
ABI <0.9 at baseline and with data at 12-month follow-up, ABI
increased from 0.6460.15 to 0.9060.20 (P0.001). Rutherford clas-
sification at 12 months decreased by at least one category compared
to baseline in 90.3% of patients (Table 5). Scores on the Walking
Impairment Questionnaire increased from 32623 at baseline to 616
30 (P < 0.001) and health utility scores on the EQ-5D questionnaire
significantly improved from 0.6760.19 to 0.8060.21 (P < 0.001),
amongst those with data at 12 months.
The data were stratified by the diabetic status. Patients with diabe-
tes were more likely to be obese (35.5% vs. 16.0%, P < 0.001), have
had a previous coronary revascularization (47.2% vs. 26.4%, P < 0.001)
and had more severely calcified lesions (50.3% vs. 35.5%, P 5 0.004).
Other key lesion characteristics in diabetics versus nondiabetics were:
mean lesion length: 7.1 cm vs. 7.7 cm (P 5 0.230), CTO: 22.4% vs.
36.2% (P 5 0.004), and restenotic (10.2% vs. 3.7%, P 5 0.008). The pri-
mary patency rate per Kaplan-Meier estimate at day 365 in patients
with diabetes was 81.0% vs. 81.5% in patients without diabetes (log-
rank P value50.9714) (Figure 2D). The rates of freedom from CD-TLR
at day 365 were 95.1% and 90.3%, respectively (P value by log-
rank50.4738).
The primary patency rate at day 365 per Kaplan-Meier estimate
was higher in males than females (84.5% vs.72.8%, log-rank P val-
ue50.015). The rate of freedom from CD-TLR was 96.2% in males and
90.7% in females at day 365 (P value by log-rank50. 0370). Baseline
characteristics were similar between genders including a mean lesion
length was 7.5 and 7.4 cm and total occlusion was present in 29.8% and
35.4%, in males and females, respectively. As expected, the reference
vessel diameter, was larger in males (5.01 mm vs. 4.52 mm, P < 0.001).
Procedural characteristics were similar, with the exception of a higher
stenting rate in males (21.0% vs. 15.0%, P5 0.192) while the occurrence
of geographic miss was lower in males (11.6% vs. 18.4%, P 5 0.067).
Geographic miss was defined by the angiographic core lab as segments
proximal or distal to the treated lesion that were subjected to injury dur-
ing pre and/or postdilatation but were not covered by study device.
In total, 72 lesions in 72 patients were stented. The majority were
in subjects with a single treated lesion (n 5 60) while twelve subjects
had an additional treated lesion that was not stented. The baseline
demographics of the subjects with a stented lesion were similar to the
entire cohort. Of the stented lesions, the mean lesion length was
8.5 cm, 59.2% were CTOs, and 40.3% were severely calcified. Reasons
for bail-out stenting included 36 residual stenoses >50% only, 12 dis-
sections only, and 24 both residual stenosis and dissection. However,
not all of these lesions met the protocol-required degree of residual
stenosis or grade of dissection (grade D or greater) for stenting based
on the site-reported data. The angiographic core laboratory data were
reviewed for the subjects with stented lesions. According to the core
laboratory data 39 (9.4%) lesions met the protocol requirements for
stenting. Per Kaplan-Meier (KM) estimate at day 365, the freedom
from CD-TLR rate was 88.6% and the primary patency rate was 78.3%
for stented patients.
4 | DISCUSSION
The ILLUMENATE Global Study builds on the growing body of evidence
with the Stellarex DCB. The primary patency rate observed in this study
was 81.4%, consistent with the 1 year primary patency rates in the
ILLUMENATE FIH Study (89.5%), ILLUMENATE Pivotal Study (82.3%),
and the ILLUMENATE EU RCT (89.0%) [17–19]. The primary patency
rate in the DCB arms of IN.PACT SFA at 12 months was 86.6% [20]
and 73.5% in LEVANT 2 [3]. The CD-TLR rate at 1 year in the
ILLUMENATE Global Study was 6.2%, also consistent with results
observed in ILLUMENATE Pivotal (7.9%) [19] and ILLUMENATE EU
RCT (5.9%) [21]. This outcome is also comparable to 4.6% in IN.PACT
SFA [22] and half the rate observed in the LEVANT 2 Study (12.3%) [3].
This study enrolled a particularly high number of CTOs (31.3%)
and the high proportion of lesions that were located within the distal
femoropopliteal region; 47.1% of lesions were located in the distal SFA
and popliteal artery, including 28 (13.9%) of which were located
entirely within the popliteal artery. Popliteal involvement has been
shown to have a significantly lower patency rate than lesions located
solely in the SFA [23].
The periprocedural stent rate was 17.3%, higher than in IN.PACT
SFA (7.3%) and LEVANT 2 (2.5%). ILLUMENATE Pivotal reported a
stent rate of 6.0% and in ILLUMENATE EU RCT it was 15.4%. Peripro-
cedural stent rates are inconsistent over different studies without a
definitive explanation other than investigator dependency. Assessment
of angiographic core lab data within this study indicted 9.4% of lesions
treated met the predefined criteria for bail-out stenting. Therefore, the
stenting rate does not appear to be related to the performance of the
study device, but rather due to investigator treatment practices.
Notably, the primary patency in patients with diabetes was similar
to those without diabetes. The patency rates were 81.0% and 81.5%,
TABLE 5 Key 12-month outcomes
Assessment 12-Mo result
Primary patencya 81.4%
Freedom from primary safety eventa 94.8%
All-cause mortalityb 0.6% (2/355)
CD-TLRb 6.2% (22/354)
Improvement in Rutherford classificationc 90.3% (306/339)
Change from baseline 22.161.1 (339)
Improvement in composite WIQ scorec 83.6% (265/317)
Change from baseline 28.76 29.3 (317)
Improvement in EQ 5-D indexc 66.8% (219/328)
Change from baseline 0.146 0.22 (328)
aKM estimate.
bThrough day 395, the denominator includes patients with an event or
those without an event having follow-up on or past the opening of the
follow-up window.
cScore at 12 months compared to baseline.
Abbreviations: CD-TLR, clinically-driven target lesion revascularization;
WIQ, walking impairment questionnaire.
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respectively (P 5 0.9714 by log rank). These outcomes are consistent
with the data observed in the ILLUMENATE EU RCT Trial [21]. Previ-
ous reports have shown diabetes to increase the risk of restenosis in
patients undergoing endovascular treatment with PTA and/stenting or
DCB [23,24].
The primary patency rate in males was significantly higher than
females (84.5% vs. 72.8%, log-rank P value is 0.015). This difference
between groups is inconsistent with findings from the two previous tri-
als on the same DCB. In the ILLUMENATE Pivotal Study, a significant
treatment effect was observed in both females and males after use of
the Stellarex DCB as compared to PTA with no significant difference in
primary patency between the genders (80.9% in males vs. 84.1% in
females, log rank P value50.4851). Likewise, there was no statistical
difference in the primary patency rates observed in the ILLUMENATE
EU RCT Study when stratified by gender (90.4% in males and 85.3% in
females, P50.3064) [21]. The only differences in vascular characteris-
tics we could identify was a larger reference vessel diameter in males
(5.016 0.86 vs. 4.5260.69, P < 0.001). Lesion length and number of
CTOs were similar in males and females. We know vessel diameter and
lesion length are directly related to vessel patency after treatment [25].
The angiographic core lab reported geographic miss occurring in
females in 18.4% of cases versus 11.6% in males P 5 0.067, also a pre-
dictor of primary patency failure [26]. While inconsistent with previous
trials on this DCB, these findings are not unusual. Female gender was
an independent predictor of restenosis in a retrospective analysis of
260 patients treated with the IN.PACT Admiral or Pacific DCBs [23].
Within the LEVANT 2 study the female cohort had a higher patency
rate when treated with an uncoated PTA catheter than with the Lutonix
DCB. More investigational work needs to be done to understand the
impact of gender on outcomes with DCB treatment in these arteries.
DCB performance and pharmacokinetic profiles differ because of
differences in the balloon platform, excipients, drug concentrations,
coating morphology, drug solubility, and coating methods [14,27,28]. A
class effect for DCBs has not been shown, therefore each DCB has to
be evaluated and outcomes from one cannot be generalized to another.
The Stellarex DCB utilizes a low dose of paclitaxel (2 mg/mm2) in a
hybrid formulation made of both amorphous and crystalline constitu-
ents combined with a polyethylene glycol (PEG) excipient. The hybrid
formulation helps maintain coating integrity compared to pure crystal-
line while allowing for sustained drug tissue release [14].
Limitations of this study include the trial design being nonblinded
and single-arm. Additionally, adjunctive devices such as atherectomy
were not assessed and outcomes cannot be generalized beyond lesions
that can be successfully predilated with PTA. Longer term follow-up
data will be critical to understand the durability of this treatment.
5 | CONCLUSIONS
The ILLUMENATE Global Study is a large prospective, multicenter,
single-arm study using the Stellarex DCB in SFA and/or popliteal
arteries down to the trifurcation. The results reported for this study are
consistent with the previously reported data with this DCB. The data
confirm the high primary patency rate and strong safety profile of the
Stellarex DCB.
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